
Keywords: AAV; adeno-associated viruses; AE; adverse event; BBB; blood-brain barrier; CLN2; ceroid lipofuscinosis neuronal type 2; CNS; central nervous system; CSF; cerebrospinal fluid; DQ; developmental quotient; ERT; enzyme replacement therapy; g7; 7-aminoacid gl